Artikel dengan mandat akses publik - Geke HospersPelajari lebih lanjut
Tidak tersedia di mana pun: 5
PET imaging of oestrogen receptors in patients with breast cancer
M van Kruchten, EGE de Vries, M Brown, EFJ de Vries, ...
The Lancet Oncology 14 (11), e465-e475, 2013
Mandat: Dutch Cancer Society
Hormone receptors as a marker of poor survival in epithelial ovarian cancer
M van Kruchten, P van der Marel, L de Munck, H Hollema, H Arts, ...
Gynecologic oncology 138 (3), 634-639, 2015
Mandat: Dutch Cancer Society
Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands
MG Franken, B Leeneman, A Jochems, MG Schouwenburg, MJB Aarts, ...
Anti-cancer drugs 29 (6), 579-588, 2018
Mandat: Netherlands Organisation for Health Research and Development
Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands
A Jochems, B Leeneman, MG Franken, MG Schouwenburg, MJB Aarts, ...
Anti-Cancer Drugs 29 (6), 572-578, 2018
Mandat: Netherlands Organisation for Health Research and Development
Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: prognostic factors associated with clinical outcomes
MG Schouwenburg, A Jochems, B Leeneman, MG Franken, ...
Melanoma Research 28 (4), 326-332, 2018
Mandat: Netherlands Organisation for Health Research and Development
Tersedia di suatu tempat: 116
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial
J Shapiro, JJB Van Lanschot, MCCM Hulshof, P van Hagen, ...
The lancet oncology 16 (9), 1090-1098, 2015
Mandat: Dutch Cancer Society
Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in …
RR Bahadoer, EA Dijkstra, B van Etten, CAM Marijnen, H Putter, ...
The Lancet Oncology 22 (1), 29-42, 2021
Mandat: Swedish Research Council, European Commission, Government of Spain, Dutch …
Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab
B Weide, A Martens, JC Hassel, C Berking, MA Postow, K Bisschop, ...
Clinical Cancer Research 22 (22), 5487-5496, 2016
Mandat: US National Institutes of Health
Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS trial
BM Eyck, JJB van Lanschot, MCCM Hulshof, BJ van der Wilk, J Shapiro, ...
Journal of Clinical Oncology 39 (18), 1995-2004, 2021
Mandat: Dutch Cancer Society
Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer–the RAPIDO trial
PJ Nilsson, B van Etten, GAP Hospers, L Påhlman, CJH van de Velde, ...
BMC cancer 13, 1-9, 2013
Mandat: Dutch Cancer Society
Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma
MW Rohaan, TH Borch, JH Van Den Berg, Ö Met, R Kessels, ...
New England Journal of Medicine 387 (23), 2113-2125, 2022
Mandat: Netherlands Organisation for Health Research and Development, Dutch Cancer …
Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma
KA Lee, AM Thomas, LA Bolte, JR Björk, LK de Ruijter, F Armanini, ...
Nature medicine 28 (3), 535-544, 2022
Mandat: US National Institutes of Health, Cancer Research UK, UK Medical Research …
Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial
ILM Reijers, AM Menzies, ACJ Van Akkooi, JM Versluis, ...
Nature medicine 28 (6), 1178-1188, 2022
Mandat: National Health and Medical Research Council, Australia
Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer
M van Kruchten, EG de Vries, AW Glaudemans, MC van Lanschot, ...
Cancer discovery 5 (1), 72-81, 2015
Mandat: Dutch Cancer Society
Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared with long-course chemoradiotherapy and surgery: a 5-year follow-up …
EA Dijkstra, PJ Nilsson, GAP Hospers, RR Bahadoer, EMK Kranenbarg, ...
Annals of surgery 278 (4), e766-e772, 2023
Mandat: Swedish Research Council, European Commission, Government of Spain, Dutch …
Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer–Results of the international randomized …
MJM van der Valk, CAM Marijnen, B van Etten, EA Dijkstra, DE Hilling, ...
Radiotherapy and Oncology 147, 75-83, 2020
Mandat: Swedish Research Council, Government of Spain, Dutch Cancer Society
CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed …
AE Slagter, EPM Jansen, HWM van Laarhoven, JW van Sandick, ...
Bmc Cancer 18, 1-12, 2018
Mandat: Dutch Cancer Society
Association of anti-TNF with decreased survival in steroid refractory ipilimumab and anti-PD1–treated patients in the Dutch melanoma treatment registry
RJ Verheijden, AM May, CU Blank, MJB Aarts, FWPJ van den Berkmortel, ...
Clinical Cancer Research 26 (9), 2268-2274, 2020
Mandat: Netherlands Organisation for Health Research and Development
Effect of neoadjuvant chemoradiotherapy on health-related quality of life in esophageal or junctional cancer: results from the randomized CROSS trial
BJ Noordman, MGE Verdam, SM Lagarde, MCCM Hulshof, P Van Hagen, ...
Journal of Clinical Oncology 36 (3), 268-275, 2018
Mandat: Dutch Cancer Society
Dutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands
A Jochems, MG Schouwenburg, B Leeneman, MG Franken, ...
European Journal of Cancer 72, 156-165, 2017
Mandat: Netherlands Organisation for Health Research and Development
Informasi terbitan dan pendanaan ditentukan secara otomatis oleh program komputer